New partnership with Nippon Shinyaku strengthens the path toward developing and commercializing a promising therapy for patients with rare inflammatory diseases
Lausanne, Switzerland, 4 August 2026 – Swiss biotechnology company AB2 Bio has reached an important milestone after receiving an early payment of USD 30 million from Japanese pharmaceutical company Nippon Shinyaku as part of a licensing agreement for the United States. The partnership is expected to accelerate the development and future commercialization of AB2 Bio’s lead therapy for a rare and life-threatening inflammatory disease.
The agreement centers on Tadekinig alfa, an innovative therapy designed to treat Primary Monogenic IL-18-driven Hyperinflammatory Syndrome, an ultra-rare autoimmune condition caused by genetic disorders including NLRC4 mutation and XIAP deficiency. Patients with these conditions experience severe inflammation that can lead to multiple organ failure if left untreated, and there are currently no approved therapies specifically developed for these diseases.
Under the agreement, Nippon Shinyaku has taken up the exclusive rights to commercialize Tadekinig alfa in the United States for its primary indication. AB2 Bio will continue leading regulatory activities, including preparations for submitting its Biologics License Application to the US Food and Drug Administration, while retaining worldwide rights for other disease indications outside the scope of the agreement.
The USD 30 million payment represents an important step in supporting the therapy’s continued development. Beyond the initial funding, the collaboration also includes the potential for additional development, commercial milestone payments, and future royalties if the treatment reaches the market successfully. This structure enables both companies to share the responsibilities of bringing the therapy to patients while supporting long-term innovation in rare disease treatment.
Rare diseases often affect small patient populations, making drug development both scientifically challenging and financially demanding. Partnerships between biotechnology innovators and established pharmaceutical companies have become an increasingly common approach to accelerate research, expand clinical development, and improve patient access to new therapies. Such collaborations combine scientific expertise with commercial capabilities, helping promising treatments move more efficiently from the laboratory to the healthcare system.
Tadekinig alfa has already received several important regulatory designations, including Orphan Drug Designation in both the United States and Europe. It has also been granted Breakthrough Therapy Designation and Rare Pediatric Disease Designation in the United States, reflecting its potential to address a significant unmet medical need for patients with very limited treatment options.
The partnership also highlights the growing importance of international collaboration in the biotechnology industry. By combining AB2 Bio’s scientific innovation with Nippon Shinyaku’s experience in developing and commercializing therapies for rare diseases in the US market, both companies aim to improve the chances of delivering new treatment options to patients who urgently need them.
As investment in precision medicine and orphan drug development continues to grow worldwide, strategic licensing agreements such as this one demonstrate how collaboration can help overcome the financial and operational challenges of developing therapies for rare diseases. For patients and healthcare providers, these partnerships offer renewed hope that innovative treatments can reach the market faster and improve outcomes for conditions that have long lacked effective therapeutic options.
